Dosing underway in Celldex Therapeutics' CDX-0159 early-stage skin disorder study [Seeking Alpha]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Seeking Alpha
HealthcareDosing underway in Celldex Therapeutics' CDX-0159 early-stage skin disorder studyOct. 13, 2020 8:34 AM ET|Celldex Therapeutics, Inc. (CLDX)Vandana Singh(NASDAQ:dosed the first patientPhase 1b studyCDX-0159 is a humanized monoclonal antibody that binds the KIT receptor tyrosine kinase, which is expressed in a variety of cells that mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells.The 40-subject study will assess the safety of multiple ascending doses of CDX-0159 in patients with CSU who remain symptomatic despite treatment with antihistamines. Secondary and exploratory objectives include pharmacokinetic and pharmacodynamic assessments.Results are anticipated in 2H of 2021.Click to subscribe to real-time analytics on CLDXNow read:Chembio Diagnostics: A Reset Of Expectations While Still Chasing The COVID Opportunity »
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics: Rising High, With Room For Further Growth [Seeking Alpha]Seeking Alpha
- Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
CLDX
Earnings
- 5/6/24 - Beat
CLDX
Sec Filings
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- 4/25/24 - Form ARS
- CLDX's page on the SEC website